Endoscopic Sleeve Gastroplasty for Obesity Management
Author Information
Author(s): Dayyeh Barham K., Stier Christine, Alqahtani Aayed, Sharaiha Reem, Bandhari Mohit, Perretta Silvana, Jirapinyo Sigh Pichamol, Prager Gerhard, Cohen Ricardo V.
Primary Institution: Mayo Clinic, Rochester, USA
Hypothesis
Is endoscopic sleeve gastroplasty (ESG) an effective treatment for obesity?
Conclusion
Endoscopic sleeve gastroplasty (ESG) is an effective and safe treatment for obesity, particularly for patients who are not suitable candidates for metabolic bariatric surgery.
Supporting Evidence
- 44 articles included in the systematic review encompassed 15,714 patients receiving ESG.
- The mean baseline BMI was 37.56 kg/m2.
- The pooled serious adverse event rate was 1.25%, indicating ESG is relatively safe.
- Significant weight loss was observed at various time points post-ESG.
- Quality of evidence from the randomized controlled trial was rated as moderate.
Takeaway
Endoscopic sleeve gastroplasty helps people lose weight without major surgery, making it a good option for those who can't have traditional surgery.
Methodology
A comprehensive systematic review and meta-analysis were conducted following PRISMA and Cochrane guidelines.
Potential Biases
Potential biases from observational study designs and lack of randomization.
Limitations
The quality of evidence from observational studies was very low due to biases and lack of randomization.
Participant Demographics
The mean age was 44.24 years, with 83.2% female participants.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 40.98–55.09 for 6 months %EWL
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website